2012.4.19pcr标准下化意义(福州).pptVIP

* References Branford S, et al. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia. 2003;(17):2401-2409. Quintas-Cardama A, et al. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood. 2009;113:6315-6321. Muller MC, et al. Molecular Response to First Line Imatinib Therapy is Pr